Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II trial with safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin chemotherapy for the treatment of advanced soft tissue sarcoma.
Authors
Matthew Ingham
Columbia University College of Physicans and Surgeons, New York, NY
Matthew Ingham, Shing Mirn Lee, Sahil Doshi, Susana Hernandez, Shahnaz V. Singh-Kandah, Zoe Singer, Ovidiu C. Trifan, Gary K. Schwartz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT03719430
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr TPS85)
Abstract #
TPS85
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
First Author: Sminu (Sam) Bose
First Author: Mark H. O'Hara
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress.
First Author: Jeesun Yoon